Saltz L - Search Results

1

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: saltz l. J Natl Cancer Inst. 2015 Feb 24;107(3):dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25713148 Free PMC article.

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.

Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP. Saltz LB, et al. Cancer. 1995 Feb 1;75(3):782-5. doi: 10.1002/1097-0142(19950201)75:3<782::aid-cncr2820750306>3.0.co;2-i. Cancer. 1995. PMID: 7828128 Clinical Trial.

4

Adjuvant treatment of colorectal cancer.

Saltz LB, Kelsen DP. Saltz LB, et al. Annu Rev Med. 1997;48:191-202. doi: 10.1146/annurev.med.48.1.191. Annu Rev Med. 1997. PMID: 9046955 Review.

5

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

6

Irinotecan in the first-line treatment of colorectal cancer.

Saltz LB. Saltz LB. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):54-8. Oncology (Williston Park). 1998. PMID: 9726092 Review.

7

A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.

O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DP. O'Reilly EM, et al. Among authors: saltz lb. Cancer Invest. 1999;17(3):195-200. doi: 10.3109/07357909909021421. Cancer Invest. 1999. PMID: 10099658 Clinical Trial.

8

Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.

Enzinger PC, Ilson DH, Saltz LB, Martin LK, Kelsen DP. Enzinger PC, et al. Among authors: saltz lb. Cancer. 1999 Mar 15;85(6):1213-7. doi: 10.1002/(sici)1097-0142(19990315)85:6<1213::aid-cncr1>3.0.co;2-n. Cancer. 1999. PMID: 10189124 Clinical Trial.

9

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma.

Cheng PN, Saltz LB. Cheng PN, et al. Among authors: saltz lb. Cancer. 1999 Sep 15;86(6):944-8. Cancer. 1999. PMID: 10491519

10

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Saltz LB, et al. N Engl J Med. 2000 Sep 28;343(13):905-14. doi: 10.1056/NEJM200009283431302. N Engl J Med. 2000. PMID: 11006366 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

495 results

Search Page